Subtype
Autonomic Nervous System Neoplasm
CI-CAN-00000468Explore in graph →
Non-malignant32 active trials3 evidence items
- NCIt
- C5112
Loading cancer entity…
Subtype
CI-CAN-00000468Explore in graph →
Clinical trials
148 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03923257 | Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents | withdrawn | Phase 1 / Phase 2 | 0 | Sue O'DorisioOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT02831179 | Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor | withdrawn | Phase 1 | 0 | Vanderbilt-Ingram Cancer CenterOTHER | 0 | Sep 28, 2017 | clinicaltrials |
| NCT01941849 |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma(VIBRaNT) |
| withdrawn |
| Phase 1 |
| 0 |
| University College, LondonOTHER |
| 1 |
| Dec 21, 2015 |
| clinicaltrials |
Data updated 23 days agoSource updated Jun 8, 2021source: clinicaltrials